Filing Flows › AstraZeneca (AZN) › Q3 2026 › vs Q2 2026
AstraZeneca (AZN) Q3 2026 vs Q2 2026 (quarter over quarter)
AstraZeneca's revenue rose $825M (+5%) from $15.4B in Q2 2026 to $16.2B in Q3 2026. Gross margin 81.8% against 83.6% (-1.8 pts).
AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 81.8% | 83.6% | -1.8 pts |
| Operating margin | 27.1% | 20.6% | +6.5 pts |
| Net margin | 19.2% | 16.3% | +2.9 pts |
| Free cash flow margin | 31.4% | 24.8% | +6.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $16.2B | $15.4B | $825M | +5% |
| Gross profit | $13.3B | $12.9B | $402M | +3% |
| Cost of revenue | $2.9B | $2.5B | $423M | +17% |
| Operating profit | $4.4B | $3.2B | $1.2B | +39% |
| Operating expenses | $8.9B | $9.7B | −$821M | -8% |
| Pre-tax earnings | $4.0B | $2.8B | $1.2B | +41% |
| Other expense, net | $429M | $365M | $64.0M | +18% |
| Net earnings | $3.1B | $2.5B | $608M | +24% |
| Income tax | $842M | $291M | $551M | +189% |
| Working capital & other | $2.6B | $2.1B | $579M | +28% |
| Operating cash flow | $5.8B | $4.6B | $1.2B | +26% |
| Free cash flow (OCF − capex) | $5.1B | $3.8B | $1.3B | +33% |
| Capital expenditures | $676M | $763M | −$87.0M | -11% |
Questions
How much did AstraZeneca's revenue grow quarter over quarter in Q3 2026?
AstraZeneca's revenue rose $825M (+5%) from $15.4B in Q2 2026 to $16.2B in Q3 2026. Gross margin 81.8% against 83.6% (-1.8 pts).